MOH Q1 2026: Adjusted EPS Beats by 82%, Guidance Reaffirmed — Rate-Trend Gap Market Resolves YES

Molina Healthcare reported Q1 2026 adjusted EPS of $2.35 against the $1.29 consensus (an 82% beat) and reaffirmed its FY2026 guidance of at least $5.00 adjusted EPS on approximately $42 billion of premium revenue. The stock has rallied roughly 33% off its Q4 lows near $118, closing pre-earnings at $169. Beneath the beat, revenue was down 3.2% year over year, the Medicaid attrition guide widened from 2% to 6% as California’s undocumented immigrant status policy drove disproportionate disenrollment, and one of our six forecast markets resolved YES when management disclosed Medicaid rates at 4% against a 5% medical cost trend. No signal labels changed across our three MOH lenses. Our MOH analysis posture holds at SEVERE_CONCERN.

The Numbers

What Q1 Actually Validated

Three elements of the Q1 release are genuinely positive relative to our Q4 2025 thesis. Adjusted EPS of $2.35 tracks well ahead of the $1.25 pro-rata needed to hit the $5.00 annual floor, and CFO Mark Keim noted that annualized Q1 trend would have the full year below the 5% assumption. Low and no-utilizer share fell to its lowest level ever (7.5 points below the pandemic peak and below pre-pandemic levels), supporting management’s contention that the 250 basis point acuity shift that inflated 2025’s 7.5% trend is “largely behind us.” And for the first time in eighteen months, management cited off-cycle Medicaid rate updates from multiple states, framing them as upside to the reaffirmed guide.

The reaffirmation language itself matters. Holding the guide steady after a quarter ahead of expectations, CEO Joe Zubretsky explicitly said they could “produce loss ratios north of 93% and still hit our guidance for the rest of the year,” framing the conservatism as protective rather than hedging. That buffer is quantitatively verifiable: 92.9% full-year Medicaid MCR guidance against a Q1 actual of 92.0% implies roughly 100 basis points of cushion. This is a different tonal register than the Q4 2025 call, where management missed FY2025 guidance by 21% and failed to quantify their own 2026 assumptions.

What Q1 Did Not Fix

Revenue is still contracting. Total Q1 revenue of $10.796 billion is down 3.2% year over year, and premium revenue guidance of $42 billion for 2026 is roughly 2% below 2025’s $42.5 billion. Medicaid membership attrition guidance widened materially from an original 2% expected annual decline to 6%, with management ending the year at approximately 4.5 million Medicaid members rather than the ~5.0 million originally modeled. The driver is concentrated: California UIS policy changes, with Illinois, New York, and Texas adding pressure.

Structural regulatory compression through 2029 remains intact. The FY2025 10-K quantified OBBBA’s impact at a 15-20% Medicaid Expansion reduction by 2029. Management’s verbal tone on the Q1 call was materially softer (“minor and gradual through 2027 and 2028”), but the filed quantification stands unretracted. Provider tax caps (2028), provider rate caps (2028), and community engagement requirements (2027) went unaddressed. Our Regulatory Exposure signal holds EXISTENTIAL; the confidence level eased from VERY HIGH to HIGH to reflect this divergence between spoken and filed disclosure.

Governance questions also remain open. No new Form 4 activity was disclosed on the call. The CEO’s $28M April 2025 sale near $320 is still pending the Spring 2026 proxy’s 10b5-1 plan disclosure, and no insider has bought at current levels despite the COO’s August 2025 $1.56M purchase at $156. The Insider Investigator’s CONCERNING classification is unchanged.

Rate-Trend Gap Market: Resolves YES, Brier 0.4489

Our Q2 2026 rate-trend gap market asked whether MOH’s Medicaid rate-trend gap would widen beyond 200 bps OR rates would fall below 5% by the Q2 2026 10-Q filing. Keim resolved it explicitly on the Q1 call: “In Medicaid, the full year MCR of 92.9% includes rate increases of 4% and medical cost trend at 5%.” Rates at 4% are clearly below the 5% threshold. Market resolves YES.

Five Active Markets, Repriced

The highest-information active market is now the Q2 membership threshold, at essentially a coin flip. If Q2 2026 membership comes in at or below 5.0M (which the updated attrition guide implies is the base case), that would directly validate the Regulatory Reader’s FRAGILE revenue durability classification, the side of the CONDITIONAL-vs-FRAGILE debate we resolved in Q4. The OBBBA guidance market at 88% captures near-certainty of CMS action given Nebraska’s mid-2026 implementation, but note the market specifically requires a CA/TX/WA/NY waiver or formal federal rule; Nebraska alone does not resolve it. The RADV market dropped 10 points on the extrapolation methodology vacation (favorable tail reduction) combined with the clean Q1 Medicare segment.

Thesis: Price-Above-Value Holds, Magnitude Reduced

Our prior thesis assessment from February carried MOH at price-above-value with LOW confidence, at a then-price of $126.61. Both attributes carry forward. The stock’s 33.5% rally to $169 has narrowed the price-value gap but not closed it: at 33.8× the reaffirmed FY2026 adjusted EPS guide and 89× the GAAP guide, the current multiple requires a credible bridge to $10+ EPS by 2027-2028 to justify. Q1 is one quarter of operational validation consistent with the “trough year” base case (FY2026 = $5.00, FY2027 = $8-10 partial recovery). It does not validate the bull case that current multiples imply ($12-14 by 2027).

The rally is better read as a repricing of tail risk (the Q4 bear case of FY2026 <$5 with 2027 no recovery is materially less likely after Q1) than as new evidence about the bull case itself. Investor Day May 8 is the decisive near-term catalyst. Management has committed to a three-year outlook through 2029 with premium revenue, EPS, margin recovery, and M&A capital deployment quantification. If that outlook delivers a credible path to double-digit EPS supported by state-specific rate restoration assumptions, current pricing becomes more defensible. If the outlook anchors to the $5 baseline with only partial margin expansion, the stock is vulnerable to re-rating lower. We flag the event; we do not predict it.